Mary Wilson
Well-known member
Week 2, 4–10 January 2025
This week’s topics
1. Overview of respiratory virus epidemiology in the EU/EEA
2. Measles – Multi-country (World) – Monitoring European outbreaks – monthly monitoring
3. Mpox due to monkeypox virus clade I – Belgium – 2024
4. Mpox due to monkeypox virus clade I – France – 2025
5. Mpox due to monkeypox virus clade I and II – Global outbreak – 2024
6. Middle East respiratory syndrome coronavirus (MERS-CoV) – Multi-country – Monthly update
7. Increase in respiratory viral infections – China – 2024
8. Avian influenza A(H5N1) human cases – United States – 2024
Executive Summary
Overview of respiratory virus epidemiology in the EU/EEA
• Primary and secondary care consultation rates for acute respiratory illness (ARI), influenza-like
illness (ILI) and severe acute respiratory illness (SARI) have been increasing in several
countries in recent weeks. Overall, syndromic indicators in primary and secondary care are at
levels comparable to this period in the previous two years.
• Influenza virus activity has been increasing since week 46, with the aggregate test positivity
rate in primary care in the EU/EEA at 29% in week 1 (based on data from 16 countries). While
hospital admissions due to influenza have been observed in all age groups, people aged 65
years and older have the highest risk of hospitalisation and severe outcomes. Overall, influenza
A(H1N1)pdm09 dominates the detections.
• RSV test positivity rate has remained stable over the past three weeks after rising for several weeks,
with the aggregate test positivity rate in primary care in the EU/EEA at 10% in week 1. Children
under five years of age have the highest risk for hospitalisation and severe outcomes due to RSV.
• Following a peak in July, SARS-CoV-2 activity has gradually decreased in most EU/EEA countries
that experienced an epidemic wave during the summer. Among those who experience SARS-
CoV-2 infection, people aged 65 years and older remain in the age group at the highest risk of
hospitalisation and severe outcomes due to COVID-19. ...
https://www.ecdc.europa.eu/sites/de...icable-disease-threats-report-week-2-2025.pdf
This week’s topics
1. Overview of respiratory virus epidemiology in the EU/EEA
2. Measles – Multi-country (World) – Monitoring European outbreaks – monthly monitoring
3. Mpox due to monkeypox virus clade I – Belgium – 2024
4. Mpox due to monkeypox virus clade I – France – 2025
5. Mpox due to monkeypox virus clade I and II – Global outbreak – 2024
6. Middle East respiratory syndrome coronavirus (MERS-CoV) – Multi-country – Monthly update
7. Increase in respiratory viral infections – China – 2024
8. Avian influenza A(H5N1) human cases – United States – 2024
Executive Summary
Overview of respiratory virus epidemiology in the EU/EEA
• Primary and secondary care consultation rates for acute respiratory illness (ARI), influenza-like
illness (ILI) and severe acute respiratory illness (SARI) have been increasing in several
countries in recent weeks. Overall, syndromic indicators in primary and secondary care are at
levels comparable to this period in the previous two years.
• Influenza virus activity has been increasing since week 46, with the aggregate test positivity
rate in primary care in the EU/EEA at 29% in week 1 (based on data from 16 countries). While
hospital admissions due to influenza have been observed in all age groups, people aged 65
years and older have the highest risk of hospitalisation and severe outcomes. Overall, influenza
A(H1N1)pdm09 dominates the detections.
• RSV test positivity rate has remained stable over the past three weeks after rising for several weeks,
with the aggregate test positivity rate in primary care in the EU/EEA at 10% in week 1. Children
under five years of age have the highest risk for hospitalisation and severe outcomes due to RSV.
• Following a peak in July, SARS-CoV-2 activity has gradually decreased in most EU/EEA countries
that experienced an epidemic wave during the summer. Among those who experience SARS-
CoV-2 infection, people aged 65 years and older remain in the age group at the highest risk of
hospitalisation and severe outcomes due to COVID-19. ...
https://www.ecdc.europa.eu/sites/de...icable-disease-threats-report-week-2-2025.pdf
